Neurol India Close
 

Table 1: Summary of phase III clinical trials of serotonin targets: DFN-11 (sumatriptan injection, 3 mg), DFN-02 (intranasal sumatriptan 10 mg), and lasmiditan (5-HT1F receptor agonists)

Table 1: Summary of phase III clinical trials of serotonin targets: DFN-11 (sumatriptan injection, 3 mg), DFN-02 (intranasal sumatriptan 10 mg), and lasmiditan (5-HT<sub>1F</sub> receptor agonists)